losartan and everolimus

losartan has been researched along with everolimus in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bieri, M; Farkas, A; Ligeti, N; Marti, HP; Meier, B; Mohacsi, P; Oroszlán, M	1

Reviews

1 review(s) available for losartan and everolimus

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

1 other study(ies) available for losartan and everolimus

Article	Year
Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transplant immunology, 2010, Volume: 23, Issue:3 Topics: Albumins; Angiotensin II; Cell Line; Down-Regulation; Drug Therapy, Combination; Endocytosis; Epithelial Cells; Everolimus; Humans; Immunosuppressive Agents; Kidney Tubules, Proximal; Losartan; Low Density Lipoprotein Receptor-Related Protein-2; Ramipril; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Signal Transduction; Sirolimus	2010

Article

Year

Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway.

Transplant immunology, 2010, Volume: 23, Issue:3

Topics: Albumins; Angiotensin II; Cell Line; Down-Regulation; Drug Therapy, Combination; Endocytosis; Epithelial Cells; Everolimus; Humans; Immunosuppressive Agents; Kidney Tubules, Proximal; Losartan; Low Density Lipoprotein Receptor-Related Protein-2; Ramipril; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Signal Transduction; Sirolimus

2010